SCHEMBL12212778

SCHEMBL12212778

CC(C)(C)c1ccc2c(c1)N(COP(=O)(O)O)C(=O)CO2

nearest known ligand 0.64

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 2/20 0.64
▸ POLB P06746 1/20 0.58
▸ L3MBTL1 Q9Y468 1/20 0.55
▸ KDM4E B2RXH2 2/20 0.48
▸ MEN1 O00255 1/20 0.48
▸ KMT2A Q03164 1/20 0.48
▸ HTT P42858 2/20 0.44
▸ TSHR P16473 2/20 0.44
▸ LMNA P02545 1/20 0.43
▸ TP53 P04637 1/20 0.43
▸ PIK3CG P48736 2/20 0.43
▸ USP2 O75604 1/20 0.42
▸ PLK1 P53350 1/20 0.41
▸ KMO O15229 1/20 0.40
▸ BRD4 O60885 1/20 0.39
▸ CYP1A2 P05177 1/20 0.38
▸ CYP3A4 P08684 1/20 0.38
▸ CYP2D6 P10635 1/20 0.38
▸ CYP2C19 P33261 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12236664 0.82 HTT (0.45) ALDH1A1POLBL3MBTL1KDM4EKMT2A
SCHEMBL17083429 0.80 ALDH1A1 (0.72) ALDH1A1POLBL3MBTL1KDM4EMEN1
SCHEMBL12212770 0.78 ALDH1A1 (0.38) ALDH1A1POLBL3MBTL1KDM4EKMT2A
SCHEMBL12212777 0.78 TSHR (0.41) ALDH1A1POLBL3MBTL1MEN1KMT2A
SCHEMBL12212779 0.78 CYP1A2 (0.47) ALDH1A1POLBL3MBTL1MEN1KMT2A
SCHEMBL12212780 0.77 ALDH1A1 (0.40) ALDH1A1POLBL3MBTL1KDM4EMEN1
SCHEMBL4106294 0.75 ALDH1A1 (0.65) ALDH1A1POLBL3MBTL1KDM4EMEN1
SCHEMBL762019 0.73 ALDH1A1 (0.61) ALDH1A1POLBL3MBTL1KDM4EMEN1
SCHEMBL12212808 0.72 SYK (0.47) —
SCHEMBL17277951 0.71 HTT (0.38) ALDH1A1POLBKDM4EHTTTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110251177-A1 2, 4-PYRIMIDINEDIAMINE COMPOUNDS AND PRODRUGS THEREOF AND THEIR USES RIGEL PHARMACEUTICALS, INC. (US) 2011-10-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110251177-A1 2, 4-PYRIMIDINEDIAMINE COMPOUNDS AND PRODRUGS THEREOF AND THEIR USES TYMP, DPYD, TYMS ALDH1A1 617/4885POLB 206/4885L3MBTL1 2301/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback